Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
3 clinical trials · Condition
◉ Watch Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
| Record | Firm | Date |
|---|---|---|
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy (NCT06834373) | Mayo Clinic | 2025-04-02 |
| Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087) | Lapo Alinari | 2023-03-06 |
| Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT02443077) | National Cancer Institute (NCI) | 2016-10-12 |
Track Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type automatically
Every clearance here is in the API, with alerts when new ones post.